Haven Capital Group, Inc. Iovance Biotherapeutics, Inc. Transaction History
Haven Capital Group, Inc.
- $90.8 Billion
- Q1 2025
A detailed history of Haven Capital Group, Inc. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Haven Capital Group, Inc. holds 121,911 shares of IOVA stock, worth $213,344. This represents 0.45% of its overall portfolio holdings.
Number of Shares
121,911
Previous 124,449
2.04%
Holding current value
$213,344
Previous $921 Million
55.91%
% of portfolio
0.45%
Previous 0.87%
Shares
2 transactions
Others Institutions Holding IOVA
# of Institutions
336Shares Held
247MCall Options Held
1.34MPut Options Held
1.61M-
Vanguard Group Inc Valley Forge, PA27.8MShares$48.6 Million0.0% of portfolio
-
Mhr Fund Management LLC New York, NY24.4MShares$42.7 Million12.15% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$37.1 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY12.7MShares$22.2 Million1.77% of portfolio
-
State Street Corp Boston, MA11MShares$19.3 Million0.0% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $276M
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...